ES2320525T3 - Piridinas y piridazinas sustituidas con actividad inhibidora de la angiogenesis. - Google Patents
Piridinas y piridazinas sustituidas con actividad inhibidora de la angiogenesis. Download PDFInfo
- Publication number
- ES2320525T3 ES2320525T3 ES00978215T ES00978215T ES2320525T3 ES 2320525 T3 ES2320525 T3 ES 2320525T3 ES 00978215 T ES00978215 T ES 00978215T ES 00978215 T ES00978215 T ES 00978215T ES 2320525 T3 ES2320525 T3 ES 2320525T3
- Authority
- ES
- Spain
- Prior art keywords
- substituted
- alkyl
- alkylamino
- optionally substituted
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000033115 angiogenesis Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 12
- 125000004429 atom Chemical group 0.000 abstract 11
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 229910052760 oxygen Inorganic materials 0.000 abstract 8
- 229910052717 sulfur Inorganic materials 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000004414 alkyl thio group Chemical group 0.000 abstract 4
- 125000003107 substituted aryl group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000005114 heteroarylalkoxy group Chemical group 0.000 abstract 3
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- -1 amino, amino Chemical group 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40760099A | 1999-09-28 | 1999-09-28 | |
| US407600 | 1999-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2320525T3 true ES2320525T3 (es) | 2009-05-25 |
Family
ID=23612752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES00978215T Expired - Lifetime ES2320525T3 (es) | 1999-09-28 | 2000-09-26 | Piridinas y piridazinas sustituidas con actividad inhibidora de la angiogenesis. |
Country Status (35)
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL154034A0 (en) * | 2000-08-09 | 2003-07-31 | Astrazeneca Ab | Indole, azaindole and indazole derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals |
| AU9598601A (en) | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| CA2471314A1 (en) * | 2001-12-21 | 2003-07-24 | Bayer Pharmaceuticals Corporation | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives |
| TWI299664B (en) | 2003-01-06 | 2008-08-11 | Osi Pharm Inc | (2-carboxamido)(3-amino)thiophene compounds |
| ES2318276T3 (es) * | 2003-03-11 | 2009-05-01 | Novartis Ag | Uso de los derivados de la isoquinolina para tratar el cancer y las enfermedades relacionadas con la quinasa map. |
| WO2004089412A1 (ja) * | 2003-04-08 | 2004-10-21 | Mitsubishi Pharma Corporation | 特異的ｎａｄ(ｐ)ｈオキシダーゼ抑制剤 |
| WO2005044788A1 (ja) | 2003-11-11 | 2005-05-19 | Eisai Co., Ltd. | ウレア誘導体およびその製造方法 |
| KR100553398B1 (ko) * | 2004-03-12 | 2006-02-16 | 한미약품 주식회사 | 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체 |
| WO2006030941A1 (ja) | 2004-09-13 | 2006-03-23 | Eisai R & D Management Co., Ltd. | スルホンアミド含有化合物の血管新生阻害物質との併用 |
| US8772269B2 (en) | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
| EP1797881B1 (en) | 2004-09-17 | 2009-04-15 | Eisai R&D Management Co., Ltd. | Medicinal composition with improved stability and reduced gelation properties |
| WO2007015578A1 (ja) | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を検定する方法 |
| US8304406B2 (en) | 2006-04-15 | 2012-11-06 | Bayer Intellectual Property Gmbh | Compounds for treating pulmonary hypertension |
| AU2007252506C1 (en) | 2006-05-18 | 2012-07-19 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| EP2065372B1 (en) | 2006-08-28 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
| CN101848895B (zh) | 2007-11-09 | 2013-10-23 | 卫材R&D管理有限公司 | 血管新生抑制物质和抗肿瘤性铂络合物的组合使用 |
| CN101481380B (zh) * | 2008-01-08 | 2012-10-17 | 浙江医药股份有限公司新昌制药厂 | 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途 |
| JP5898074B2 (ja) | 2010-06-25 | 2016-04-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤 |
| JP6021805B2 (ja) | 2011-04-18 | 2016-11-09 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| CA2889866A1 (en) | 2012-12-21 | 2014-06-26 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| ES2687968T3 (es) | 2013-05-14 | 2018-10-30 | Eisai R&D Management Co., Ltd. | Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib |
| CN103396361B (zh) * | 2013-07-24 | 2016-05-04 | 中国人民解放军第二军医大学 | 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用 |
| BR112017002827B1 (pt) | 2014-08-28 | 2023-04-18 | Eisai R&D Management Co., Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
| HUE064614T2 (hu) | 2015-02-25 | 2024-04-28 | Eisai R&D Man Co Ltd | Eljárás egy kinolin-származék keserû ízének elnyomására |
| WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| CN104804008B (zh) * | 2015-03-27 | 2016-03-23 | 亿腾药业（泰州）有限公司 | 一种工业化生产甲磺酸特拉替尼的方法 |
| SG11201710198YA (en) | 2015-06-16 | 2018-01-30 | Eisai R&D Man Co Ltd | Anticancer agent |
| CA2994925C (en) | 2015-08-20 | 2023-08-29 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| KR102539920B1 (ko) | 2017-02-08 | 2023-06-05 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 종양-치료용 약제학적 조성물 |
| CN107129502B (zh) * | 2017-04-13 | 2022-08-05 | 泰州亿腾景昂药业股份有限公司 | EOC315 Mod.I晶型化合物及其制备方法 |
| CN110831597A (zh) | 2017-05-16 | 2020-02-21 | 卫材R&D管理有限公司 | 肝细胞癌的治疗 |
| JP7624404B2 (ja) * | 2019-04-22 | 2025-01-30 | ミラティ セラピューティクス，インク． | Ｐｒｃ２阻害剤としてのナフチリジン誘導体 |
| CN112830932B (zh) * | 2020-12-25 | 2022-04-08 | 泰州亿腾景昂药业股份有限公司 | 特拉替尼的游离碱晶型及其制备方法与用途 |
| IL312506A (en) | 2021-11-08 | 2024-07-01 | Progentos Therapeutics Inc | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1453897A (fr) * | 1965-06-16 | 1966-07-22 | Dérivés du thiophène et de thiéno pyridazines | |
| GB1094044A (en) * | 1965-07-12 | 1967-12-06 | Vantorex Ltd | Phthalazine derivatives |
| FR1516777A (fr) * | 1966-08-02 | 1968-02-05 | Innothera Lab Sa | Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation |
| GB1293565A (en) * | 1969-05-03 | 1972-10-18 | Aspro Nicholas Ltd | Aminophthalazines and pharmaceutical compositions thereof |
| JPH03106875A (ja) * | 1989-09-20 | 1991-05-07 | Morishita Pharmaceut Co Ltd | １―（３―ピリジルメチル）フタラジン誘導体 |
| AU705229B2 (en) * | 1994-08-09 | 1999-05-20 | Eisai R&D Management Co., Ltd. | Fused pyridazine compound |
| IL118631A (en) * | 1995-06-27 | 2002-05-23 | Tanabe Seiyaku Co | History of pyridazinone and processes for their preparation |
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| WO2000009495A1 (en) * | 1998-08-11 | 2000-02-24 | Novartis Ag | Isoquinoline derivatives with angiogenesis inhibiting activity |
| AU766081B2 (en) * | 1999-03-30 | 2003-10-09 | Novartis Ag | Phthalazine derivatives for treating inflammatory diseases |
| AR025068A1 (es) * | 1999-08-10 | 2002-11-06 | Bayer Corp | Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis |
| US6706731B2 (en) * | 2000-02-09 | 2004-03-16 | Novartis Ag | Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase |
-
2000
- 2000-09-22 CO CO00072226A patent/CO5200835A1/es active IP Right Grant
- 2000-09-22 DO DO2000000070A patent/DOP2000000070A/es unknown
- 2000-09-22 AR ARP000104981A patent/AR025752A1/es not_active Application Discontinuation
- 2000-09-22 GT GT200000158A patent/GT200000158A/es unknown
- 2000-09-25 MY MYPI20051063A patent/MY143580A/en unknown
- 2000-09-25 PE PE2000001004A patent/PE20010607A1/es not_active Application Discontinuation
- 2000-09-25 MY MYPI20004467A patent/MY135058A/en unknown
- 2000-09-25 TW TW089119700A patent/TW593315B/zh not_active IP Right Cessation
- 2000-09-25 PA PA20008503201A patent/PA8503201A1/es unknown
- 2000-09-25 MY MYPI20051064A patent/MY143377A/en unknown
- 2000-09-26 PL PL366342A patent/PL205957B1/pl unknown
- 2000-09-26 DE DE60041548T patent/DE60041548D1/de not_active Expired - Lifetime
- 2000-09-26 RU RU2002111414/04A patent/RU2260008C2/ru active
- 2000-09-26 SK SK591-2002A patent/SK287417B6/sk not_active IP Right Cessation
- 2000-09-26 HU HU0202704A patent/HU230223B1/hu not_active IP Right Cessation
- 2000-09-26 EP EP00978215A patent/EP1228063B1/en not_active Expired - Lifetime
- 2000-09-26 CN CNB2005101271105A patent/CN100422173C/zh not_active Expired - Lifetime
- 2000-09-26 AU AU15696/01A patent/AU782820B2/en not_active Expired
- 2000-09-26 CA CA2385817A patent/CA2385817C/en not_active Expired - Lifetime
- 2000-09-26 ES ES00978215T patent/ES2320525T3/es not_active Expired - Lifetime
- 2000-09-26 AT AT00978215T patent/ATE422494T1/de not_active IP Right Cessation
- 2000-09-26 NZ NZ518589A patent/NZ518589A/en not_active IP Right Cessation
- 2000-09-26 UA UA2002043504A patent/UA75053C2/uk unknown
- 2000-09-26 KR KR1020087021380A patent/KR100895572B1/ko not_active Expired - Lifetime
- 2000-09-26 KR KR1020087021379A patent/KR100895571B1/ko not_active Expired - Lifetime
- 2000-09-26 EE EEP200200161A patent/EE05258B1/xx not_active IP Right Cessation
- 2000-09-26 KR KR1020027003972A patent/KR100890473B1/ko not_active Expired - Lifetime
- 2000-09-26 IL IL14888000A patent/IL148880A0/xx active IP Right Grant
- 2000-09-26 WO PCT/US2000/026500 patent/WO2001023375A2/en active Application Filing
- 2000-09-26 JP JP2001526527A patent/JP4919567B2/ja not_active Expired - Lifetime
- 2000-09-26 HR HR20020308A patent/HRP20020308A2/xx not_active IP Right Cessation
- 2000-09-26 MX MXPA02003156A patent/MXPA02003156A/es active IP Right Grant
- 2000-09-26 BR BRPI0014382A patent/BRPI0014382B8/pt not_active IP Right Cessation
- 2000-09-26 RS YUP-229/02A patent/RS50369B/sr unknown
- 2000-09-26 CZ CZ2002-1444A patent/CZ304767B6/cs not_active IP Right Cessation
- 2000-09-26 CN CNB2005101271092A patent/CN100422172C/zh not_active Expired - Lifetime
- 2000-09-26 CN CNB008163693A patent/CN100374435C/zh not_active Expired - Lifetime
-
2002
- 2002-03-26 NO NO20021520A patent/NO20021520L/no unknown
- 2002-04-09 ZA ZA200202760A patent/ZA200202760B/xx unknown
- 2002-04-23 BG BG106637A patent/BG65860B1/bg unknown
- 2002-04-26 MA MA26619A patent/MA25563A1/fr unknown
-
2008
- 2008-08-11 IL IL193367A patent/IL193367A/en active IP Right Grant
- 2008-08-11 IL IL193368A patent/IL193368A/en active IP Right Grant
-
2011
- 2011-07-15 AR ARP110102558A patent/AR082231A2/es unknown
- 2011-07-15 AR ARP110102559A patent/AR082232A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2320525T3 (es) | Piridinas y piridazinas sustituidas con actividad inhibidora de la angiogenesis. | |
| RU2002111414A (ru) | Замещенные пиридины и пиридазины, обладающие способностью ингибировать ангиогенез | |
| WO2001092255A3 (en) | Epothilone derivatives and methods for making and using the same | |
| PE20020228A1 (es) | Compuestos organicos como inhibidores de 3',5' guanosin monofosfato ciclico fosfodiesterasa | |
| PE20010815A1 (es) | Uso de inhibidores de 3`,5'-guanosinmonofosfato ciclico fosfodiesterasa para el tratamiento de la hipertension pulmonar | |
| AR043508A1 (es) | 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores | |
| PE20011166A1 (es) | Piridinas, pirimidinas, purinonas, pirrolopirimidinonas y pirrolopiridinonas como antagonistas del factor liberador de corticotropina | |
| YU11299A (sh) | Derivati indazola | |
| AR100696A2 (es) | Uso de un compuesto de 15-ceto-prostaglandina para fabricar una composición para tratar estreñimiento inducido por drogas | |
| LU90283I2 (fr) | Sporanox soluté buvable et ses dérivés pharmaceutiquement acceptables | |
| DE69705819D1 (de) | Angiogenesis hemmende pyridazinamine | |
| AR007456A1 (es) | Compuestos derivados de indazol sustituido y composiciones farmaceuticas que lo contienen | |
| AR060431A1 (es) | Compuestos para el tratamiento de la hipertension pulmonar | |
| GB1314903A (en) | Quinazoline derivatives | |
| DK1237584T3 (da) | Receptorbindende konjugater | |
| IE812420L (en) | Spiro compounds | |
| DK1129096T3 (da) | CRF-receptorantagonister og fremgangsmåder, der er relateret dertil | |
| CO5180637A1 (es) | Piradazinas sustituidas y piradazinas fusionadas con actividad inhibidora de angiogenesis | |
| LT2001078A (en) | Use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones as medicaments | |
| EA200100716A1 (ru) | Способ профилактики рака молочной железы | |
| DE69824313D1 (de) | Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen | |
| AP9801377A0 (en) | Tricyclic erythromycin derivatives. | |
| BR0116123A (pt) | Carbazóis antitumorais | |
| DK190983A (da) | 2,4-diamino-5-(substituerede)pyrimidiner, fremgangsmaade til deres fremstilling og mellemprodukter derfor | |
| ATE247955T1 (de) | Selenophen-antitumormittel |